Equities

Cytek Biosciences Inc

Cytek Biosciences Inc

Actions
  • Price (EUR)6.65
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+45.83%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments262341365
Total Receivables, Net565130
Total Inventory614832
Prepaid expenses107.154.60
Other current assets, total2.566.700.71
Total current assets392454432
Property, plant & equipment, net29285.85
Goodwill, net161010
Intangibles, net234.334.74
Long term investments------
Note receivable - long term------
Other long term assets3.392.961.67
Total assets494519463
LIABILITIES
Accounts payable3.034.813.03
Accrued expenses242517
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.570.58--
Other current liabilities, total281813
Total current liabilities564933
Total long term debt1.652.270
Total debt2.212.850
Deferred income tax------
Minority interest00.250.34
Other liabilities, total444325
Total liabilities1019458
SHAREHOLDERS EQUITY
Common stock0.130.140.13
Additional paid-in capital423443424
Retained earnings (accumulated deficit)(29)(17)(20)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(1.28)(0.7)0.90
Total equity393425405
Total liabilities & shareholders' equity494519463
Total common shares outstanding131135134
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.